Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 8Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma 22Breast Neoplasms 16Leukemia 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Hodgkin Disease 11Neuroblastoma 10Lymphoma, Follicular 10Burkitt Lymphoma 10Leukemia, Myeloid, Acute 9Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neutropenia 8Lymphoma, Non-Hodgkin 8Leukemia, Myelomonocytic, Acute 8Leukemia, Monocytic, Acute 8Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Neoplasms, Plasma Cell 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Malignant mesenchymal tumor 5Congenital Abnormalities 5Rhabdomyosarcoma 4Leukemia, Myeloid, Chronic-Phase 4Kidney Neoplasms 4Immunoglobulin Light-chain Amyloidosis 4Endometrial Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Filgrastim × Clear all
NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡